PI3K pathway inhibition in GBM—is there a signal?
- PMID: 26170259
- PMCID: PMC4588764
- DOI: 10.1093/neuonc/nov124
PI3K pathway inhibition in GBM—is there a signal?
Comment on
-
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18. Neuro Oncol. 2015. PMID: 25526733 Free PMC article. Clinical Trial.
-
Phase II study of PX-866 in recurrent glioblastoma.Neuro Oncol. 2015 Sep;17(9):1270-4. doi: 10.1093/neuonc/nou365. Epub 2015 Jan 20. Neuro Oncol. 2015. PMID: 25605819 Free PMC article. Clinical Trial.
References
-
- Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–153. - PubMed
-
- Eshleman JS, Carlson BL, Mladek AC, et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24):7291–7297. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical